• 1
    Cairo MS, Coiffier B, Reiter A, Younes A. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 2010; 149: 578586.
  • 2
    Cheuk DK, Chiang AK, Chan GC, Ha SY. Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer. Cochrane Database Syst Rev 2010; (6): CD006945.
  • 3
    Mughal TI, Foringer JR, Ejaz A, Coiffier B. An integrated clinical approach for the identification, prevention, and treatment of tumour lysis syndrome. Cancer Treat Rev 2010; 36: 164176.
  • 4
    Pui C, Jeha S, Irwin D. Recombinant urate oxidase in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia 2001; 15: 15051509.
  • 5
    Hummel M, Reiter S, Adam K, Hehlmann R, Buchheidt D. Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase. Eur J Haematol 2008; 80: 331336.
  • 6
    Giraldez M, Puto K. A single, fixed dose of rasburicase (6 mg maximum) for treatment of tumor lysis syndrome in adults. Eur J Haematol 2010; 85: 177179.
  • 7
    Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumours lysis syndrome: an evidence based review. J Clin Oncol 2008; 28: 27672778.
  • 8
    Gertz MA. Managing tumour lysis syndrome in 2010. Leuk Lymphoma 2010; 51: 179180.
  • 9
    Sanofi-Aventis. Fasturtec (Rasburicase) Approved Product Information. Macquarie Park: Sanofi-Aventis Australia Pty Ltd, 2010.
  • 10
    Steel S, Coutsouvelis J, McKendrick J. Single dose rasburicase in tumour lysis: one hospitals' experience. Asia Pac J Clin Oncol 2008; 4: 1820.
  • 11
    Trifilio SM, Pi J, Zook J, Golf M, Coyle K, Greenberg D, Newman D, Koslosky M, Mehta J. Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignancies. Bone Marrow Transplant 2011; 46: 800805.
  • 12
    Trifilio S, Gordon L, Singhal S, Tallman M, Evens A, Rashid K, Fishman M, Masino K, Pi J, Mehta J. Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. Bone Marrow Transplant 2006; 37: 9971001.
  • 13
    Hummel M, Buchheidt D, Reiter S, Bergmann J, Adam K, Hehlmann R. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia – successful treatment and prevention of TLS with low-dose rasburicase. Eur J Haematol 2005; 75: 518521.
  • 14
    Knoebel RW, Lo M, Crank CW. Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome. J Oncol Pharm Pract 2011; 17: 147154.
  • 15
    Eaddy M, Seal B, Tangirala M, Davies EH, O'Day K. Economic comparison of rasburicase and allopurinol for treatment of tumour lysis syndrome in pediatric patients. Am J Health Syst Pharm 2010; 67: 21102114.
  • 16
    Darmon M, Guichard I, Vincent F. Rasburicase and tumor lysis syndrome: lower dosage, consideration of indications, and hyperhydration. J Clin Oncol 2011; 29: 6768.
  • 17
    Chiang J, Chan A, Lian T, Tay K, Quek R, Tao M, Lim ST. Management of tumour lysis syndrome with a single fixed dose of rasburicase in Asian lymphoma patients: a case series and literature review. Asia Pac J Clin Oncol 2011; 7: 351356.